Shane J. Schaffer and Dr. Ann Childress, CEO and consultant at Cingulate Inc. CING, respectively, were guest speakers at Benzinga’s All Access on June 3rd, 2022.
Cingulate is a biopharmaceutical company engaging in the research and development of new product candidates for the treatment of central nervous system disorders - specially its innovative Precision Timed Release (PTR) Technology.
Watch the full interview here.
Photo by Mitchell Griest on Unsplash
CINGCingulate Inc
$3.65-0.27%
Edge Rankings
Momentum6.89
Growth-
Quality-
Value-
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in